Health Care Related Organization

Roche; MediLink Therapeutics; YL201; antibody-drug conjugate; ADC; B7-H3; TMALIN platform; small-cell lung cancer; SCLC; solid tumors; licensing deal; oncology; China biotech

AstraZeneca appoints Rick R. Suarez to lead U.S. BioPharmaceuticals business and $50B investment drive

1 week ago talkbio0Tagged AstraZeneca, Biological Factors, Head of US, Investments, President brand of dental material, Rick R. Suarez, Surgical aspects, U.S., Virginia manufacturing facility, Wilmington Delaware

AstraZeneca; Rick R. Suarez; US President; Head of US BioPharmaceuticals Business Unit; $50 billion US investment; Virginia manufacturing facility; US operations; biopharmaceuticals; revenue goal 2030; Wilmington Delaware

Independent expert group to review HPV vaccine evidence after US recommendation change

1 week ago talkbio0Tagged ACIP, CDC, Centers for Disease Control and Prevention (U.S.), Childhood, CIDRAP, disbanded, Gardasil, HPV vaccine, Immunization Schedule, independent review, recommendation change, single-dose schedule, U.S., Vaccine Integrity Project

HPV vaccine; Vaccine Integrity Project; independent review; CDC recommendation change; single-dose schedule; ACIP disbanded; CIDRAP; Robert F. Kennedy Jr.; US childhood immunization schedule; Gardasil

Sanofi calls FDA rejection of potential MS blockbuster tolebrutinib “unexpected” amid evolving agency views on benefit–risk

1 week ago talkbio0Tagged BTK inhibitor, Complete Response Letter, DILI, Mississippi (geographic location), Multiple Sclerosis, nrSPMS, PERSEUS trial, perspectives, Progressive, Rejection, sanofi, Tolebrutinib, United States Food and Drug Administration

Sanofi; tolebrutinib; multiple sclerosis; nrSPMS; BTK inhibitor; FDA rejection; complete response letter; DILI; primary progressive MS; Perseus trial; evolving FDA perspectives